HC Wainwright & Co. Reiterates Buy on Processa Pharma, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Processa Pharma (NASDAQ:PCSA) and maintained a price target of $8.
June 12, 2024 | 10:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Processa Pharma and maintained a price target of $8, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to a short-term increase in PCSA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100